Recombinant Human Erythropoietin

Product Description

Recombinant Human Erythropoietin
Catalog number: B2010356
Lot number: Batch Dependent
Expiration Date: Batch dependent
Volume/Weight: 10 ug
pH: 7.4 upon reconstitution
Supplied as: Lyophilized Powder
Appearance: Powder
Applications: highly pure Recombinant Human Erythropoietin expressed in CHO. This protein acts as a protein that protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. This product is for in vitro Research Use Only and is NOT for human or animal use.
Storage: -20C
Keywords: rHuEPO; Epoetin; EPO
Grade: Biotechnology grade. All components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Feusner J, Hastings C. Recombinant human erythropoietin in pediatric
oncology: a review. Med Pediatr Oncol. 2002 Oct;39(4):463-8.

2: Macdougall IC, Akizawa T, Berns JS, Bernhardt T, Krueger T. Effects of
Molidustat in the Treatment of Anemia in CKD. Clin J Am Soc Nephrol. 2019 Jan
7;14(1):28-39.

3: Adamson JW, Ludwig H. Predicting the hematopoietic response to recombinant
human_erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer.
Oncology. 1999;56(1):46-53.

4: Fishbane S, Singh B, Kumbhat S, Wisemandle WA, Martin NE. Intravenous Epoetin
Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney
Disease. Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1204-1214.

5: Vadhan-Raj S. Recombinant_human erythropoietin in combination with other
hematopoietic cytokines in attenuating chemotherapy-induced multilineage
myelosuppression: brief communication. Semin Hematol. 1996 Jan;33(1 Suppl
1):16-8.

6: Roye DP Jr. Recombinant human erythropoietin and blood management in
pediatric spine surgery. Orthopedics. 1999 Jan;22(1 Suppl):s158-60.

7: Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF.
Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic
kidney disease. Cochrane Database Syst Rev. 2017 Aug 7;8(8):CD009904.

8: Azmandian J, Abbasi MR, Pourfarziani V, Nasiri AA, Ossareh S, Ezzatzadegan
Jahromi S, Sanadgol H, Amini S, Shahvaroughi Farahani A. Comparing Therapeutic
Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia
in End-Stage Renal Disease Hemodialysis Patients. Am J Nephrol.
2018;48(4):251-259.

9: Grzegorzewska AE, Sucharzewska-Tomczak M. Wybiórcza aplazja czerwonokrwinkowa
jako powikłanie leczenia rekombinowana ludzka erytropoetyna Pure red cell
aplasia as a complication of treatment with recombinant human erythropoietin.
Pol Merkur Lekarski. 2004 Oct;17(100):407-9. Polish.

Products Related to Recombinant Human Erythropoietin : Proteins